Strictly Laboratory Research Use Only: Not approved for human or clinical consumption. HPLC Purity Tested (≥99%).

Purity:

RETATRUTIDE (RETA) 30 MG/ML

Vial Size / Concentration: 

$90.00

/ vial

Triple-Receptor Metabolic Research Peptide

Retatrutide is an investigational peptide studied for its simultaneous activity at three metabolic hormone receptors: GLP-1, GIP, and glucagon receptors. This triple-agonist mechanism distinguishes retatrutide from single- and dual-receptor incretin compounds.

Research has examined retatrutide in relation to appetite regulation, glucose metabolism, insulin signaling, lipid metabolism, energy intake, and energy expenditure. Its combined receptor activity provides researchers with a unique model for investigating how multiple metabolic signaling pathways interact.

The glucagon-receptor component is of particular interest because it may influence energy expenditure and hepatic metabolism, while GLP-1 and GIP receptor activity is associated with incretin signaling, glucose regulation, and appetite-related pathways.

Clinical research has demonstrated substantial effects on body weight and metabolic markers, while studies continue to characterize its efficacy, safety, and longer-term metabolic effects. Retatrutide remains an investigational compound and is not FDA-approved as of August 2026.

Research Focus: GLP-1 • GIP • Glucagon Receptors • Metabolic Signaling • Appetite Regulation • Glucose Metabolism • Insulin Signaling • Energy Expenditure • Lipid Metabolism • Body-Weight Research

Concentration: Retatrutide — 30 mg/mL

RESEARCH USE ONLY NOT FOR HUMAN OR ANIMAL USE

CAS Number:

Molecular Formula:

Molecular Weight:

Appearance:

ISO 9001:2015 Verified Laboratory Compound

Submit Research Specification

All synthesis requests are handled under rigorous laboratory non-disclosure agreements.